The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Preliminary safety & tolerability of CD19x22 CAR T-cell therapy in patients with R/R NHL
Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, comments on the preliminary safety and tolerability of a bicistronic CD19xCD22-directed CAR T-cell therapy in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL). Dr Kamdar highlights the promising early data, with two complete responses and one partial response observed in eight efficacy-evaluable patients, and notes that the study has shown good safety signals, with no grade 3 or higher cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) seen to date. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
